183 related articles for article (PubMed ID: 26251417)
1. Quantification of β-Amyloidosis and rCBF with Dedicated PET, 7 T MR Imaging, and High-Resolution Microscopic MR Imaging at 16.4 T in APP23 Mice.
Maier FC; Keller MD; Bukala D; Bender B; Mannheim JG; Brereton IM; Galloway GJ; Pichler BJ
J Nucl Med; 2015 Oct; 56(10):1593-9. PubMed ID: 26251417
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal amyloid imaging in mouse brain with 11C-PIB: comparison of APP23, Tg2576, and APPswe-PS1dE9 mouse models of Alzheimer disease.
Snellman A; López-Picón FR; Rokka J; Salmona M; Forloni G; Scheinin M; Solin O; Rinne JO; Haaparanta-Solin M
J Nucl Med; 2013 Aug; 54(8):1434-41. PubMed ID: 23833271
[TBL] [Abstract][Full Text] [Related]
3. Use of T1-weighted/T2-weighted magnetic resonance ratio to elucidate changes due to amyloid β accumulation in cognitively normal subjects.
Yasuno F; Kazui H; Morita N; Kajimoto K; Ihara M; Taguchi A; Yamamoto A; Matsuoka K; Takahashi M; Nakagawara J; Iida H; Kishimoto T; Nagatsuka K
Neuroimage Clin; 2017; 13():209-214. PubMed ID: 28003959
[TBL] [Abstract][Full Text] [Related]
4. Relative 11C-PiB Delivery as a Proxy of Relative CBF: Quantitative Evaluation Using Single-Session 15O-Water and 11C-PiB PET.
Chen YJ; Rosario BL; Mowrey W; Laymon CM; Lu X; Lopez OL; Klunk WE; Lopresti BJ; Mathis CA; Price JC
J Nucl Med; 2015 Aug; 56(8):1199-205. PubMed ID: 26045309
[TBL] [Abstract][Full Text] [Related]
5. High amyloid-β deposition related to depressive symptoms in older individuals with normal cognition: a pilot study.
Yasuno F; Kazui H; Morita N; Kajimoto K; Ihara M; Taguchi A; Yamamoto A; Matsuoka K; Kosaka J; Kudo T; Iida H; Kishimoto T; Nagatsuka K
Int J Geriatr Psychiatry; 2016 Aug; 31(8):920-8. PubMed ID: 26766490
[TBL] [Abstract][Full Text] [Related]
6. Binding of
Hashimoto T; Yokota C; Koshino K; Temma T; Yamazaki M; Iguchi S; Shimomura R; Uehara T; Funatsu N; Hino T; Minematsu K; Iida H; Toyoda K
Ann Nucl Med; 2017 Apr; 31(3):227-234. PubMed ID: 28220365
[TBL] [Abstract][Full Text] [Related]
7. Mutual effect of cerebral amyloid β and peripheral lymphocytes in cognitively normal older individuals.
Yasuno F; Kazui H; Kajimoto K; Ihara M; Morita N; Taguchi A; Yamamoto A; Matsuoka K; Takahashi M; Nakagawara J; Tsuji M; Iida H; Kishimoto T; Nagatsuka K
Int J Geriatr Psychiatry; 2017 Dec; 32(12):e93-e99. PubMed ID: 28111810
[TBL] [Abstract][Full Text] [Related]
8. Reproducibility of automated simplified voxel-based analysis of PET amyloid ligand [11C]PIB uptake using 30-min scanning data.
Aalto S; Scheinin NM; Kemppainen NM; Någren K; Kailajärvi M; Leinonen M; Scheinin M; Rinne JO
Eur J Nucl Med Mol Imaging; 2009 Oct; 36(10):1651-60. PubMed ID: 19495749
[TBL] [Abstract][Full Text] [Related]
9. In vivo mapping of amyloid toxicity in Alzheimer disease.
Frisoni GB; Lorenzi M; Caroli A; Kemppainen N; Någren K; Rinne JO
Neurology; 2009 Apr; 72(17):1504-11. PubMed ID: 19398705
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal PET-MRI reveals β-amyloid deposition and rCBF dynamics and connects vascular amyloidosis to quantitative loss of perfusion.
Maier FC; Wehrl HF; Schmid AM; Mannheim JG; Wiehr S; Lerdkrai C; Calaminus C; Stahlschmidt A; Ye L; Burnet M; Stiller D; Sabri O; Reischl G; Staufenbiel M; Garaschuk O; Jucker M; Pichler BJ
Nat Med; 2014 Dec; 20(12):1485-92. PubMed ID: 25384087
[TBL] [Abstract][Full Text] [Related]
11. Characterization of an APP/tau rat model of Alzheimer's disease by positron emission tomography and immunofluorescent labeling.
Filip T; Mairinger S; Neddens J; Sauberer M; Flunkert S; Stanek J; Wanek T; Okamura N; Langer O; Hutter-Paier B; Kuntner C
Alzheimers Res Ther; 2021 Oct; 13(1):175. PubMed ID: 34656177
[TBL] [Abstract][Full Text] [Related]
12. Quantitative PET and Histology of Brain Biopsy Reveal Lack of Selective Pittsburgh Compound-B Binding to Intracerebral Amyloidoma.
Groot C; Tolboom N; Ikonomovic MD; Lammertsma AA; Boon BDC; Barkhof F; Scheltens P; Klunk WE; Rozemuller AJM; Ossenkoppele R; van Berckel BNM
J Alzheimers Dis; 2018; 65(1):71-77. PubMed ID: 30040724
[TBL] [Abstract][Full Text] [Related]
13. Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET.
Tolboom N; Yaqub M; van der Flier WM; Boellaard R; Luurtsema G; Windhorst AD; Barkhof F; Scheltens P; Lammertsma AA; van Berckel BN
J Nucl Med; 2009 Feb; 50(2):191-7. PubMed ID: 19164243
[TBL] [Abstract][Full Text] [Related]
14. Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging.
Chen MK; Mecca AP; Naganawa M; Finnema SJ; Toyonaga T; Lin SF; Najafzadeh S; Ropchan J; Lu Y; McDonald JW; Michalak HR; Nabulsi NB; Arnsten AFT; Huang Y; Carson RE; van Dyck CH
JAMA Neurol; 2018 Oct; 75(10):1215-1224. PubMed ID: 30014145
[TBL] [Abstract][Full Text] [Related]
15. Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B.
Meyer PT; Hellwig S; Amtage F; Rottenburger C; Sahm U; Reuland P; Weber WA; Hüll M
J Nucl Med; 2011 Mar; 52(3):393-400. PubMed ID: 21321269
[TBL] [Abstract][Full Text] [Related]
16. PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease.
Toyama H; Ye D; Ichise M; Liow JS; Cai L; Jacobowitz D; Musachio JL; Hong J; Crescenzo M; Tipre D; Lu JQ; Zoghbi S; Vines DC; Seidel J; Katada K; Green MV; Pike VW; Cohen RM; Innis RB
Eur J Nucl Med Mol Imaging; 2005 May; 32(5):593-600. PubMed ID: 15791432
[TBL] [Abstract][Full Text] [Related]
17. Comparison of MR-less PiB SUVR quantification methods.
Bourgeat P; Villemagne VL; Dore V; Brown B; Macaulay SL; Martins R; Masters CL; Ames D; Ellis K; Rowe CC; Salvado O; Fripp J;
Neurobiol Aging; 2015 Jan; 36 Suppl 1():S159-66. PubMed ID: 25257985
[TBL] [Abstract][Full Text] [Related]
18.
Meier SR; Sehlin D; Roshanbin S; Falk VL; Saito T; Saido TC; Neumann U; Rokka J; Eriksson J; Syvänen S
J Nucl Med; 2022 Feb; 63(2):302-309. PubMed ID: 34088777
[TBL] [Abstract][Full Text] [Related]
19. In vivo SPECT imaging of amyloid-β deposition with radioiodinated imidazo[1,2-a]pyridine derivative DRM106 in a mouse model of Alzheimer's disease.
Chen CJ; Bando K; Ashino H; Taguchi K; Shiraishi H; Shima K; Fujimoto O; Kitamura C; Matsushima S; Uchida K; Nakahara Y; Kasahara H; Minamizawa T; Jiang C; Zhang MR; Ono M; Tokunaga M; Suhara T; Higuchi M; Yamada K; Ji B
J Nucl Med; 2015 Jan; 56(1):120-6. PubMed ID: 25476539
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal assessment of cerebral β-amyloid deposition in mice overexpressing Swedish mutant β-amyloid precursor protein using 18F-florbetaben PET.
Rominger A; Brendel M; Burgold S; Keppler K; Baumann K; Xiong G; Mille E; Gildehaus FJ; Carlsen J; Schlichtiger J; Niedermoser S; Wängler B; Cumming P; Steiner H; Herms J; Haass C; Bartenstein P
J Nucl Med; 2013 Jul; 54(7):1127-34. PubMed ID: 23729696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
